mopidamol has been researched along with Experimental Mammary Neoplasms in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (75.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lichtner, RB; Schirner, M; Schneider, MR | 1 |
Butcher, RW; Goka, TJ; Lichtner, RB; Nicolson, GL | 1 |
Gallick, GE; Lichtner, RB; Nicolson, GL | 1 |
Lichtner, RB; Nicolson, GL | 1 |
4 other study(ies) available for mopidamol and Experimental Mammary Neoplasms
Article | Year |
---|---|
The stable prostacyclin analogue Cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3 rat mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Epoprostenol; Female; Lung Neoplasms; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mopidamol; Rats; Rats, Inbred F344 | 1994 |
Direct effects of the pyrimido-pyrimidine derivative RA 233 (Rapenton) on rat 13762NF mammary tumor cell clones in vitro.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; Cell Survival; Clone Cells; Cyclic AMP; Female; Kinetics; Mammary Neoplasms, Experimental; Mopidamol; Pyrimidines; Rats | 1987 |
Pyrimido-pyrimidine modulation of EGF growth-promoting activity and p21ras expression in rat mammary adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Cell Division; Epidermal Growth Factor; Mammary Neoplasms, Experimental; Mopidamol; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; Rats | 1988 |
The pyrimido-pyrimidine derivatives RA 233 and RX-RA 85 affect growth and cytoskeletal organization of rat mammary adenocarcinoma cells.
Topics: Actin Cytoskeleton; Adenocarcinoma; Animals; Cell Line; Cell Survival; Cytoskeleton; Dose-Response Relationship, Drug; Mammary Neoplasms, Experimental; Microtubules; Mopidamol; Phosphodiesterase Inhibitors; Pyrimidines; Rats; Vacuoles | 1987 |